American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 11(65), 2021
DOI: 10.1128/aac.01137-21
Full text: Download
Clinical efficacy of the influenza antiviral baloxavir marboxil (baloxavir) is compromised by treatment-emergent variants harboring a polymerase acidic protein I38T (isoleucine-38-threonine) substitution. However, the fitness of I38T-containing influenza B viruses (IBVs) remains inadequately defined.